LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced that Smithers Avanza, a contract research organization supporting the pharmaceutical industry, is adding the Simoa HD-1 Analyzer to its Bioanalytical Laboratory. With this addition, Smithers Avanza will provide its customers with an opportunity to leverage Simoa’s unprecedented levels of sensitivity and automation capabilities in drug discovery and development.
Smithers Avanza chose the Simoa HD-1 instrument from Quanterix to complement the other instruments in the bioanalytical laboratory, allowing the company to increase testing volume and utilize the automation features to increase efficiency. Simoa enables development of methods to provide much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.
“Simoa is changing the way in which the biology of health and disease is studied by giving organizations, like Smithers Avanza, the ability to closely examine critical biomarkers to improve the probabilities of clinical trial success by over 200 percent,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “By providing accessibility to our Simoa technology, we look forward to advancements and new discoveries in both pre-clinical and clinical research that will be uncovered by Smithers Avanza customers in the future.”
“We are continuously looking at how we can provide greater value to our clients,” said Ira DuBey, Executive Vice President, Smithers Avanza Bioanalytical Services. “Adding technology such as the Simoa HD-1 that analyzes biologics and biomarkers with a very high degree of sensitivity helps us to deliver the testing results our clients are looking for.”
About Smithers Avanza
Smithers Avanza is a contract research organization (CRO) supporting the pharmaceutical industry. Our scientists have expertise in large molecule bioanalysis, assay development, validation and sample analysis at our GLP- and GCP-compliant and CLIA-certified laboratory.
Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.